iEV
Phase 2Biologic
iEV is one of 66 biologic programs targeting Cognitive impairment. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
65
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
72 competitors in Cognitive Impairment
#DrugCompanyPhaseTrials
1Ritalin
NovartisApproved
Epidiolex
Jazz PharmaceuticalsApproved
Marinol
Jazz PharmaceuticalsApproved
Intropin
PfizerApproved
Brintellix
TakedaApproved
Lithobid
SSolvay Pharmaceuticals
Approved
Lamictal
GGlaxo Dba Glaxosmithkline
Approved
Bendopa
MMerz North America, Inc.
Approved
Topamax
WWim Janssens
Approved
Altoprev
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Cognitive impairment1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for iEV. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- SShanghai 6th People's Hospital